STOCK TITAN
  1. Home
  2. News
  3. ATAI

ATAI Life Sciences N.V. - ATAI STOCK NEWS

Welcome to our dedicated news page for ATAI Life Sciences N.V. (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on ATAI Life Sciences N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATAI Life Sciences N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATAI Life Sciences N.V.'s position in the market.

News
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Rhea-AI Summary
atai Life Sciences announced the publication of Beckley Psytech’s Phase 1 study of BPL-003 in the Journal of Psychopharmacology. BPL-003, a novel benzoate salt formulation of 5-MeO-DMT, showed safety, tolerability, and reliable induction of psychedelic effects in healthy participants. The study demonstrated rapid onset and short duration of effects, with potential for scalable single-dose treatment models. Positive participant feedback and plans for Phase 2a and 2b studies in Alcohol Use Disorder and Treatment Resistant Depression highlight the promising future of BPL-003.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Rhea-AI Summary
Atai Life Sciences (ATAI) announces strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies for mental health disorders. Positive Phase 2a results for BPL-003 in TRD patients show rapid and durable antidepressant effects. Dosing starts for VLS-01 in a Phase 1b study for TRD. Financially, the company expects funding to last into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.06%
Tags
earnings
-
News
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
Rhea-AI Summary
atai Life Sciences (ATAI) announces positive initial results from BPL-003 Phase 2a study in Treatment Resistant Depression (TRD). A single dose demonstrated rapid and durable antidepressant effects, with 45% of patients in remission at week 12. BPL-003 showed good safety profile and was well-tolerated. Phase 2b study in 225 TRD patients underway with top-line results expected in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
clinical trial
News
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
Rhea-AI Summary
atai Life Sciences initiates Phase 1b trial for VLS-01, a rapid-acting antidepressant for treatment-resistant depression, with promising early results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
clinical trial
-
News
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
atai Life Sciences to participate in a panel discussion at the TD Cowen conference in Boston, MA on March 4, 2024, aiming to transform mental health treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
-
News
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
Rhea-AI Summary
atai Life Sciences (ATAI) announced the appointment of Anne Johnson as Chief Financial Officer, succeeding Stephen Bardin. Johnson brings almost 20 years of biotechnology and pharmaceutical experience and will lead the company's financial organization. The interim CFO, Johnson, has demonstrated executive leadership, financial acumen, and a track record in the biopharmaceutical industry. She will work closely with CEO Florian Brand to execute the company's strategy. Stephen Bardin will continue in an advisory role until March 31, 2024, to support the transition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
management
News
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) announced a strategic investment in Beckley Psytech Limited to accelerate the development of two patent-protected, clinical-stage psychedelic candidates, BPL-003 and ELE-101. Multiple clinical readouts are anticipated within the next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24. BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.67%
Tags
clinical trial
-
News
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA, showing well-tolerated treatment and dose-dependent changes in pharmacokinetics and pharmacodynamics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.86%
Tags
clinical trial
-
News
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Rhea-AI Summary
atai Life Sciences (NASDAQ: ATAI) reported third quarter 2023 financial results and provided corporate updates. The company's $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. The Phase 2b study of RL-007 in CIAS patients is on track to report data in 2H 2024, and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. The company also announced the acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two novel 5-HT2A receptor agonists, EGX-A and EGX-B.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.13%
Tags
earnings
News
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
management
Stock ATAI logo
ATAI Life Sciences N.V.

Nasdaq:ATAI

ATAI Rankings

#3334 Ranked by Market Cap
#5001 Ranked by Stock Gains
N/A Ranked by Dividends

ATAI Stock Data

356.96M
126.68M
9.99%
28%
3.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Berlin

About ATAI

who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.